Satish Waigaonkar Honoured with Honorary Doctorate for Transformative Pharmacoeconomics Model in Public Healthcare
Mumbai/Nanded:
In a landmark moment for India’s public health ecosystem, Satish Ramchandra Waigaonkar, Director of Waiko Drugs and Pharma LLP, Nanded, has been awarded an Honorary Doctorate for developing a groundbreaking Pharmacoeconomics-Based Procurement Model. This innovative framework is transforming how government hospitals in Maharashtra select, procure, and utilize medicines—resulting in better clinical outcomes, higher transparency, and significant cost savings.
At a time when public healthcare systems face challenges of rising costs, inconsistent quality, and medicine-related inefficiencies, Waigaonkar’s model introduces a scientific, data-driven, and patient-centric approach that aligns treatment quality with economic efficiency.
A Scientific Breakthrough in Drug Procurement
Waigaonkar’s model evaluates medicines through stringent parameters before procurement, including:
- Bioavailability and clinical efficacy
- Treatment duration and recovery outcomes
- Real-world patient response data
- Quality and compliance of vendors
- Cost-effectiveness without compromising clinical value
This ensures that government hospitals procure only high-quality, clinically potent, and outcome-oriented medicines, leading to faster recovery and reduced burden on the healthcare system.
Health economists describe this breakthrough as “a model of national importance”, with potential for countrywide adoption.
Measurable Impact Across Maharashtra
In district hospitals where the model is already operational, the results have been remarkable:
- 20–30% reduction in treatment duration
- 25–40% reduction in procurement wastage
- Lower hospital bed occupancy rates
- Reduction in emergency purchases and stock-outs
- Improved transparency in drug selection and vendor assessment
By eliminating low-efficacy and poor-quality medicines, hospitals saw faster patient recovery, better antibiotic stewardship, and optimized use of government budgets.
Healthcare administrators confirm that the model has strengthened decision-making in:
- Antibiotic and antimicrobial selection
- Injectable vs. oral therapy optimisation
- Culture-sensitivity-based drug choices
- Vendor compliance and documentation verification
- High-bioavailability drug procurement
This scientific method of purchasing medicines is now considered one of Maharashtra’s most impactful healthcare innovations.
A Recognition that Redefines Public Health Standards
Upon receiving the Honorary Doctorate, Dr. Satish Waigaonkar said:
“Pharmacoeconomics is not just about reducing costs. It is about ensuring that every patient receives safe, effective, and scientifically validated treatment. This recognition belongs to the entire health department that believed in this vision.”
Officials from the Maharashtra Health Department echo the sentiment, noting that the model has become a game-changer for:
- Hospital administrators
- Procurement committees
- Pharmacy departments
- Medical colleges and rural health institutes
Plans are currently underway to implement this framework across all government medical colleges, district hospitals, and rural health institutions in the state.
A Vision for Nationwide Adoption
Experts believe that in the coming years, Waigaonkar’s Pharmacoeconomics Model should be integrated into national health procurement policies, ensuring:
- Quality-driven drug selection
- Reduction of hidden treatment costs
- Stronger supply chain efficiency
- Standardized clinical outcomes across government hospitals
As India moves toward a future of value-based healthcare, this model combines safety, science, quality, and economic efficiency—setting a new benchmark in public health management.
Connect with Satish Waigaonkar
- Facebook: https://www.facebook.com/
- Instagram: https://www.instagram.com/satishwaigaonkar
